Document:

EXHIBIT 4.5

 

THIS WARRANT AND THE SHARES OF CAPITAL
STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED BY ANY PERSON, INCLUDING A PLEDGEE,
UNLESS (1) EITHER (A) A REGISTRATION WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE SECURITIES ACT, OR (B) THE COMPANY SHALL
HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT IS
AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE WITH ALL APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS.

 

	 	Right to Purchase 100,000 Shares of Common Stock of Interleukin Genetics, Inc.

 

COMMON STOCK PURCHASE WARRANT

 

Interleukin Genetics,
Inc., a Delaware corporation (the “Company”), hereby certifies that for value received Danforth Advisors, LLC, a Massachusetts
limited liability corporation (the “Holder”), or assigns, is entitled to purchase, subject to the terms and conditions
hereinafter set forth, up to 100,000 shares of Common Stock (the “Warrant Shares”) (subject to adjustment as hereinafter
provided) at the Stated Purchase Price, payable as hereinafter provided. This Warrant is being issued pursuant to the terms of
that certain Consulting Agreement, dated September 8, 2014, by and between the Company and Holder (the “Consulting Agreement”).

 

1.  Definitions.
As used herein, the following terms shall have the following meanings, unless the context otherwise requires:

 

(a)          “Change
of Control” shall mean the occurrence of any of the following events: (i) any “Person” (as such term is used
in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than Pyxis
Innovations, Inc. or an affiliate thereof, becomes the “Beneficial Owner” (as defined in Rule 13d-3 under the Exchange
Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented
by the Company’s then outstanding voting securities pursuant to a transaction or a series of related transactions which the
Board of Directors of the Company (the “Board”) does not approve; or (ii) (A) a merger or consolidation of the Company
whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting
securities of the surviving entity or the parent of such corporation) at least fifty percent (50%) of the total voting power represented
by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding
immediately after such merger or consolidation; (B) or the Company’s stockholders approve an agreement for the sale or disposition
by the Company of all or substantially all of the Company’s assets.

 

    	 

    	 

    

 

(b)          “Common
Stock” shall mean the Company’s common stock, $0.001 par value per share.

 

(b)          “Stated
Purchase Price” shall mean the purchase price to be paid upon exercise of this Warrant in accordance with the terms hereof,
which price initially shall be $0.25 per Warrant Share. The Stated Purchase Price shall be subject to adjustment from time to time
pursuant to the provisions of Sections 5 and 6 hereof.

 

(c)          “Warrant
Expiration Date” shall mean 5:00 p.m., Eastern Time, on September 8, 2024.

 

2.  Exercise.

 

(a)          Vesting
of Warrant Shares. The Warrant Shares subject to this Warrant shall vest and become exercisable in cumulative installments
of 1/24th of the Warrant Shares on the last day of each successive month beginning September 30, 2014 during the term
of the Consulting Agreement. Notwithstanding the foregoing, 50% of the Warrant Shares shall become fully vested and exercisable
if the Company terminates the Consulting Agreement for any reason other than “for cause” (as defined in the Consulting
Agreement) before September 8, 2015 and the remaining 50% of the warrants shall become fully vested and exercisable if the Company
terminates the Consulting Agreement for any reason other than “for cause” after September 8, 2015 upon the extension
of the agreement. In addition, the Warrant granted hereby shall vest and become exercisable as to all of the Warrant Shares upon
a Change of Control during the term of the Consulting Agreement.

 

(b)          Manner
of Exercise. This Warrant may be exercised at any time or from time to time, on any day which is not a Saturday, Sunday or
holiday under the laws of the Commonwealth of Massachusetts prior to the Warrant Expiration Date, for all or any part of the Warrant
Shares that have vested pursuant to Section 2(a) above. In order to exercise this Warrant, in whole or in part, the Holder shall
deliver to the Company at its principal executive offices, or at such other office as the Company may designate by notice in writing,
(i) this originally executed Warrant and (ii) a duly executed written notice of Holder's election to exercise its Warrant in whole
or in part substantially in the form of Exhibit A attached hereto, and shall pay to the Company by check made payable to
the order of the Company or wire transfer of funds to a bank account designated by the Company an amount equal to the aggregate
purchase price for all Warrant Shares as to which this Warrant is being exercised.

 

    	-2-

    	 

    

 

(c)          Cashless
Exercise. In addition to and without limiting the rights of the Holder hereof under the terms of this Warrant, the Holder may
elect to receive, without the payment by the Holder of the Stated Purchase Price, shares of Common Stock equal to the value of
the vested Warrant Shares or any portion thereof by the surrender of this Warrant (or such portion of this Warrant being so exercised)
together with the Net Issue Election Notice annexed hereto as Exhibit B duly executed and completed, at its principal executive
offices, or at such other office as the Company may designate by notice in writing. Thereupon, the Company shall issue to the Holder
such number of fully paid, validly issued and nonassessable shares of Common Stock, as is computed using the following formula:

 

X= Y(A-B)

A

 

where

 

X = the number of shares of Common
Stock to be issued to the Holder (or such other person or persons as directed by the Holder) upon such exercise of the rights under
this Section 2(c)

 

Y = the total number of vested
Warrant Shares which the Holder has surrendered for cashless exercise

 

A = the “Fair Market Value”
of one share of Common Stock on the date that the Holder delivers the Net Issue Election Notice to the Company as provided herein

 

B = the Stated Purchase Price
in effect under this Warrant on the date that the Holder delivers the Net Issue Election Notice to the Company as provided herein

 

The “Fair Market Value”
of a share of Common Stock as of a particular date (the “Valuation Date”) shall mean the following: (y) if the Common
Stock is then listed on a stock exchange or quoted on a quotation system, the closing sale price of one share of Common Stock on
such exchange or system on the last trading day prior to the Valuation Date; or (z) if the Common Stock is not then listed on a
stock exchange or quoted on a quotation system, the Fair Market Value of one share of Common Stock as of the Valuation Date shall
be determined in good faith by the Board of Directors of the Company (the “Board”). The Board shall respond promptly
in writing to an inquiry by the Holder prior to the exercise hereunder as to the Fair Market Value of a share of Common Stock.

 

    	-3-

    	 

    

 

(d)          Issuance
of Common Stock. Upon receipt of the documents and payments described in Section 2(b) or Section 2(c), as the case may be,
the Company shall, as promptly as practicable, execute or cause to be executed, and deliver to the Holder a certificate or certificates
representing the aggregate number of full Warrant Shares (or such other stock or securities that may be issuable upon exercise
of the Warrant) issuable upon such exercise. The stock certificate or certificates so delivered shall be in the denomination specified
in said notice and shall be registered in the name of the Holder. This Warrant shall be deemed to have been exercised and a certificate
or certificates for shares of Common Stock shall be deemed to have been issued, and the Holder or any other person so designated
to be named therein shall be deemed to have become a holder of record of such shares for all purposes as of the date said notice,
together with this Warrant and the documents and payments described in Section 2(b) or 2(c), as the case may be, are received by
the Company as aforesaid. If this Warrant shall have been exercised in part, the Company shall, at the time of delivery of said
certificate or certificates, deliver to the Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased shares
of Common Stock called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

(e)          Transfer
Restriction Legend. Each certificate for Common Stock issued upon exercise of this Warrant, unless at the time of exercise
the offer and sale of the Warrant Shares are registered under the Securities Act, shall bear the following legend (and any additional
legend required by applicable law or rule) on the face thereof:

 

“”THE SECURITIES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR (B) PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL
TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.”

 

3.  Reservation of
Shares. The Company covenants that it will at all times until the Warrant Expiration Date reserve and keep available out of
its authorized and unissued Common Stock, solely for the purpose of issue upon exercise of this Warrant, such number of Warrant
Shares as shall then be issuable upon the exercise of this Warrant.

 

4.  Loss, Theft,
Destruction or Mutilation. Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant (including a reasonably detailed affidavit with respect to the circumstances of any loss, theft or destruction
of such Warrant and a customary and reasonable indemnity and surety bond, if requested by the Company), and, in the case of any
such mutilation, upon surrender and cancellation of this Warrant, the Company at its expense will execute and deliver, in lieu
hereof, a new Warrant of like tenor.

 

    	-4-

    	 

    

 

5.  Subdivision or
Combination of Common Stock. If the Company at any time subdivides (by any stock split, stock dividend, recapitalization or
otherwise) its outstanding shares of Common Stock into a greater number of shares, the Stated Purchase Price in effect immediately
prior to such subdivision will be proportionately reduced and the number of Warrant Shares issuable upon exercise of this Warrant
will be proportionately increased, and if the Company at any time combines (by reverse stock split, recapitalization or otherwise)
its outstanding shares of Common Stock into a smaller number of shares, the Stated Purchase Price in effect immediately prior to
such combination will be proportionately increased and the number of Warrant Shares issuable upon exercise of this Warrant will
be proportionately decreased.

 

6.  Consolidation,
Merger, etc. If there shall be a merger or consolidation of the Company with or into another corporation (other than a merger
or reorganization involving only a change in the state of incorporation of the Company), then as a part of such transaction, provision
shall be made so that the Holder hereof shall thereafter be entitled to receive the number of shares of stock or other securities
or property of the Company, or of the successor corporation resulting from the merger or consolidation, to which the Holder would
have been entitled if the Holder had exercised this Warrant immediately prior thereto.

 

7.  Notice of Adjustment
of Stated Purchase Price. Upon any adjustment or other change relating to the Stated Purchase Price or the securities purchasable
upon the exercise of this Warrant, then, and in each such case, the Company shall promptly prepare and deliver to Holder notice,
setting forth, in reasonable detail, the event requiring the adjustment and the method by which such adjustment was calculated.

 

8.  Fractional Shares.
The Company shall not issue fractions of shares, upon exercise of this Warrant or otherwise, or distribute certificates that evidence
fractional shares. With respect to any fraction of a share called for upon any exercise hereof, such fraction shall neither be
issued nor extinguished until the final exercise of this Warrant, in which event if a fraction is issuable, the Company shall pay
to the Holder an amount in cash equal to such fraction multiplied by the Stated Purchase Price, as adjusted to date pursuant to
Section 5 or 6.

 

9.  Holder Not Deemed
Stockholder. The Holder shall not be entitled to vote or to receive dividends or be deemed the holder of Common Stock that
may at any time be issuable upon exercise of this Warrant for any purpose whatsoever, nor shall anything contained herein be construed
to confer upon the Holder any of the rights of a stockholder of the Company or any right to vote for the election of directors
or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights, until Holder
shall have exercised this Warrant in accordance with the provisions hereof.

 

10.  Successors and
Assigns. This Warrant, and the obligations and rights of the Company hereunder, shall be binding upon and inure to the benefit
of the Company, the Holder, and their respective successors and permitted assigns.

 

    	-5-

    	 

    

 

11.  Waiver and Amendment.
Any provision of this Warrant may be amended, waived or modified only upon the written consent of the Company and the Holder.

 

12.  Notices.
Any notice, request or other communication required or permitted hereunder shall be in writing and shall be delivered in accordance
with the terms of Section 15 of the Consulting Agreement.

 

13.  Governing Law.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by the internal
laws of the State of Delaware, United States of America, without giving effect to any choice of law or conflict of law provision
or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of Delaware.

 

14.  Headings; References.
All headings used herein are used for convenience only and will not be used to construe or interpret this Warrant. Except where
otherwise indicated, all references herein to Sections refer to Sections hereof.

 

15.  Acceptance.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained
herein.

 

[Remainder of page intentionally left blank.]

 

    	-6-

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be duly executed as of September 8, 2014.

 

	 	INTERLEUKIN GENETICS, INC.
	 	 
	 	By:	 
	 	Name:  	Kenneth S. Kornman
	 	Title:  	President and CEO

 

    	-7-

    	 

    

 

EXHIBIT A

 

EXERCISE FORM

(To be signed only on exercise of Warrant)

 

Interleukin Genetics, Inc.

135 Beaver Street

Waltham, MA 02452

 

The undersigned hereby
irrevocably elects to exercise the right to purchase represented by the within Warrant for, and to purchase thereunder, _____________
shares of common stock, $0.001 par value per share, of Interleukin Genetics, Inc. (the “Common Stock”) at a price of
$_______ per share of Common Stock, and herewith makes payment of $___________ (such payment being by check made payable to the
order of Interleukin Genetics, Inc., or wire transfer of funds to a bank account designated by Interleukin Genetics, Inc., or any
combination thereof), surrenders the Warrant and all right, title and interest therein to Interleukin Genetics, Inc. and requests
that certificates for such shares be issued in the name of:

 

	 
	(Please print name, address, and social security number)
	 
	 

 

and, if said number of shares shall not
be all the shares purchasable thereunder, that a new Warrant for the balance remaining of the shares purchasable under the within
Warrant be registered in the name of the undersigned holder of the within Warrant or his Assignee as below indicated and delivered
to the address stated below.

 

	NAME OF HOLDER OR ASSIGNEE:	 	 
	 	(Please print)

 

ADDRESS OF HOLDER OR
ASSIGNEE:_____________________________________________________

 

SIGNATURE OF HOLDER:_____________________________________________

 

DATED:__________________

 

    	-8-

    	 

    

 

EXHIBIT B

 

NET ISSUE ELECTION NOTICE

(To be signed only on exercise of Warrant)

 

Interleukin Genetics, Inc.

135 Beaver Street

Waltham, MA 02452

 

The undersigned hereby elects under Section
2(c) of this Warrant to surrender the right to purchase [______________] shares of common stock, $0.001 par value per share, of
Interleukin Genetics, Inc. (the “Common Stock”) pursuant to the within Warrant and hereby requests the issuance of
[______________] shares of Common Stock. The undersigned requests that certificates for such shares be issued in the name of:

 

	 
	(Please print name, address, and social security number)
	 
	 

 

and, if said number of shares shall not
be all the shares purchasable thereunder, that a new Warrant for the balance remaining of the shares purchasable under the within
Warrant be registered in the name of the undersigned holder of the within Warrant or his Assignee as below indicated and delivered
to the address stated below.

 

	NAME OF HOLDER OR ASSIGNEE:	 	 
	 	(Please print)

 

ADDRESS OF HOLDER OR
ASSIGNEE:_____________________________________________________

 

SIGNATURE OF HOLDER:_____________________________________________

 

DATED:__________________

 

    	-9-Exhibit 10.13

 

CONSULTING AGREEMENT

 

This Consulting Agreement (the “Agreement”) is made
effective as of September 8, 2014 (the “Effective Date”), by and between Interleukin
Genetics, Inc., a Delaware corporation, with its principal place of business being 135
Beaver Street, Waltham, MA 02452 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability
corporation, with its principal place of business being 91 Middle Road, Southborough, MA 01772 (“Danforth”). The Company
and Danforth are herein sometimes referred to individually as a “Party” and collectively as the “Parties.”

 

WHEREAS, the Company is a
genetics-based personalized health company that develops genetic tests for use in the emerging personalized health market;

 

WHEREAS, Danforth
has expertise in financial and corporate operations and strategy;

 

WHEREAS, Danforth
desires to serve as an independent consultant for the purpose of providing the Company with certain strategic and financial advice
and support services, as more fully described in Exhibit A attached hereto,
(the "Services"); and 

 

WHEREAS, the Company wishes to engage Danforth
on the terms and conditions set forth herein.

 

NOW THEREFORE, in consideration of the foregoing
and for other good and valuable consideration, the receipt of which are hereby acknowledged, the Parties agree and covenant as
follows.

 

		1.	Services of Consultant. Danforth will assist the Company with matters relating to the Services.
The Services are more fully described in Exhibit A attached hereto. Danforth and the Company
will review the Services on a monthly basis to prioritize and implement the tasks listed on Exhibit A.

 

		2.	Compensation for Services. In full consideration of Danforth’s full, prompt
and faithful performance of the Services, the Company shall compensate Danforth
a consulting fee more fully described in Exhibit A (the “Consulting Fee”). Danforth
shall, from time to time, but not more frequently than twice per calendar month invoice the Company for Services rendered
and such invoice will be paid upon fifteen (15) days of receipt. Each month the Parties shall evaluate jointly the current fee
structure and scope of Services. Upon termination of this Agreement pursuant to Section 3, no compensation or benefits of any kind
as described in this Section 2 shall be payable or issuable to Danforth after the effective date of such termination.
In addition, the Company will reimburse Danforth for reasonable out-of-pocket business expenses, including but not limited
to travel and parking, incurred by Danforth in performing the Services hereunder, upon submission by Danforth of supporting documentation
reasonably acceptable to the Company. Any such accrued expenses in any given three (3) month period that exceed one thousand dollars
($1,000) shall be submitted to the Company for its prior written approval.

 

    	1

    	 

    

 

		3.	Term and Termination. The term of this Agreement will commence on the Effective Date and will continue through the anniversary
of such date in the next calendar year (the “Term”). This Agreement may be extended for an additional period by mutual
written agreement. This Agreement may be terminated by either Party hereto: (a) with Cause (as defined below), upon thirty (30)
days prior written notice to the other Party; or (b) without cause upon thirty (30) days prior written notice to the other Party.
For purposes of this Section 3, “Cause” shall include: (i) a breach of the terms of this Agreement which is not cured
within thirty (30) days of written notice of such default or (ii) the commission of any act of fraud, embezzlement or deliberate
disregard of a rule or policy of the Company.

 

		4.	Time Commitment. Danforth will devote such time to perform the Services under this
Agreement as may reasonably be required. 

 

		5.	Place of Performance. Danforth will perform the Services at such locations upon which the Company and Danforth may mutually
agree. Danforth will not, without the prior written consent of the Company, perform any of the Services at any facility or in any
manner that might give anyone other than the Company any rights to or allow for disclosure of any Confidential Information (as
defined below).

 

		6.	Compliance with Policies and Guidelines. Danforth will perform the Services in accordance with all rules or policies
adopted by the Company that the Company discloses in writing to Danforth.

 

		7.	Confidential Information. Danforth
acknowledges and agrees that during the course of performing the Services, the Company may furnish, disclose or make available
to Danforth information, including, but not limited to, material, compilations, data, formulae, models, patent disclosures, procedures,
processes, business plans, projections, protocols, results of experimentation and testing, specifications, strategies and techniques,
and all tangible and intangible embodiments thereof of any kind whatsoever (including, but not limited to, any apparatus, biological
or chemical materials, animals, cells, compositions, documents, drawings, machinery, patent applications, records and reports),
which is owned or controlled by the Company and is marked or designated as confidential at the time of disclosure or is of a type
that is customarily considered to be confidential information (collectively the “Confidential Information"). Danforth
acknowledges that the Confidential Information or any part thereof is the exclusive property
of the Company and shall not be disclosed to any third party without first obtaining the written consent of the Company. Danforth
further agrees to take all practical steps to ensure that the Confidential Information, and any part thereof, shall not be disclosed
or issued to its affiliates, agents or employees, except on like terms of confidentiality. The above provisions of confidentiality
shall apply for a period of five (5) years. 

 

    	2

    	 

    

 

		8.	Intellectual Property. Danforth agrees that all ideas, inventions, discoveries, creations,
manuscripts, properties, innovations, improvements, know-how, inventions, designs, developments, apparatus, techniques, methods,
and formulae that Danforth conceives, makes, develops or improves as a result of performing the Services, whether or not reduced
to practice and whether or not patentable, alone or in conjunction with any other party and whether or not at the request or upon
the suggestion of the Company (all of the foregoing being hereinafter collectively referred to as the “Inventions”),
shall be the sole and exclusive property of the Company. Danforth hereby assigns and agrees to assign to the Company all rights,
title and interest Danforth has or may have to Product, information, data, methods, products, processes, documentation, reports,
inventions, results (including know-how generated from failures and deviations from the specifications) and other works as a result
of performing the Services, including without limitation any records and all intellectual property rights related thereto free
and clear of all liens, claims, encumbrances, licenses and restrictions. To the extent applicable, all copyrightable works resulting
from the Services shall be “Works Made for Hire” as defined in the U.S. Copyright Act. Danforth shall execute and deliver
any documents and do such things as may be reasonably necessary or desirable in order to carry into effect the provisions of this
Section. Danforth hereby agrees in consideration of the the Company’s agreement to engage
Danforth and pay compensation for the Services rendered to the Company and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged that Danforth shall not, without the prior written consent of the Company, directly
or indirectly, consult for, or become an employee of, any company which conducts business in the Field of Interest anywhere in
the world. As used herein, the term “Field of Interest” shall mean the research,
development, manufacture and/or sale of the products resulting from the Company’s technology. The limitations on competition
contained in this Section 8 shall continue during the time that Danforth performs any Services for the Company (whether as a consultant,
employee or otherwise), and for a period of six (6) months following the termination of any such Services that Danforth
performs for the Company. If any part of this section should be determined by a court of competent jurisdiction to be unreasonable
in duration, geographic area, or scope, then this Section 8 is intended to and shall extend only for such period of time, in such
area and with respect to such activity as is determined to be reasonable. Except as expressly provided herein, nothing in this
Agreement shall preclude Danforth from consulting for or being employed by any other person or entity.

 

		9.	Non Solicitation. All personnel representing Danforth are employees or contracted
agents of Danforth. As such, they are obligated to provide the Services to the Company and are obligated to Danforth under confidentiality,
non-compete, and non-solicitation agreements. Accordingly, they are not retainable as employees or contractors by the Company and
the Company hereby agrees not to solicit, hire or retain their services for so long as they are employees or contracted agents
of Danforth and for one (1) year thereafter. Should the Company violate this restriction, it agrees to pay Danforth liquidated
damages equal to fifteen thousand ($15,000) dollars for each Danforth employee or contracted agent solicited and/or hired by the
Company in violation of this Agreement, plus Danforth’s reasonable attorneys’ fees and costs incurred in enforcing
this agreement should the Company fail or refuse to pay the liquidated damages amount in full within thirty (30) days following
its violation.

 

		10.	Placement Services. In the event that Danforth refers a potential employee to the Company and that individual is hired,
Danforth shall receive a fee equal to fifteen percent (15%) of the employee’s starting annual base salary and targeted bonus
for a full year of employment. This fee is due and owing whether an individual is hired, directly or indirectly, on a permanent
basis or on a contract or consulting basis by the Company, as a result of Danforth’s efforts within one (1) year of the date
applicant(s) are submitted to the Company. Such payment is due within ninety (90) days of the employee’s start date so long
as the hired individual is currently employed at the end of said ninety (90) day period.

 

    	3

    	 

    

  

		11.	No Implied Warranty. Except for any express warranties stated herein, the Services are provided
on an "as is" basis, and the Company disclaims any and all other warranties, conditions, or representations (express,
implied, oral or written), relating to the Services or any part thereof. Further, in performing the Services Danforth is
not engaged to disclose illegal acts, including fraud or defalcations, which may have taken place. The foregoing notwithstanding,
Danforth will promptly notify the Company if Danforth becomes aware of any such illegal acts during the performance of the Services.
Because the Services do not constitute an examination in accordance with standards established by the American Institute of Certified
Public Accountants (the “AICPA”), Danforth is precluded from expressing an opinion as to whether financial statements
provided by the Company are in conformity with generally accepted accounting principles or any other standards or guidelines promulgated
by the AICPA, or whether the underlying financial and other data provide a reasonable basis for the statements.

  

		12.	Indemnification. Each Party hereto agrees to
indemnify and hold the other Party hereto, its directors, officers, agents and employees harmless against any claim based upon
circumstances alleged to be inconsistent with such representations and/or warranties contained in this Agreement. Further, the
Company shall indemnify and hold harmless Danforth and any of its subcontractors against any claims, losses, damages or liabilities
(or actions in respect thereof) that arise out of or are based on the Services performed hereunder, except for any such claims,
losses, damages or liabilities arising out of the negligence or willful misconduct Danforth or any of its subcontractors. The
Company will endeavor to add Consultant and any applicable subcontractor to its insurance policies as additional insureds.

 

		13.	Independent Contractor. Danforth is not, nor shall Danforth be deemed to be at any time during the term of this Agreement,
an employee of the Company, and therefore Danforth shall not be entitled to any benefits provided by the Company to its employees,
if applicable. Danforth’s status and relationship with the Company shall be that of an independent contractor and consultant.
Danforth shall not state or imply, directly or indirectly, that Danforth is empowered to bind the Company without the Company's
prior written consent. Nothing herein shall create, expressly or by implication, a partnership, joint venture or other association
between the parties. Danforth will be solely responsible for payment of all charges and taxes arising from his or her relationship
to the Company as a consultant.
	 	 	 

		14.	Records. Upon termination of Danforth’s relationship with the Company, Danforth shall deliver to the Company any
property or Confidential Information of the Company relating to the Services which may be in its possession including products,
project plans, materials, memoranda, notes, records, reports, laboratory notebooks, or other documents or photocopies and any such
information stored using electronic medium.

 

    	4

    	 

    

 

		15.	Notices. Any notice under this Agreement shall be in writing (except in the case of verbal communications, emails and
teleconferences updating either Party as to the status of work hereunder) and shall be deemed delivered upon personal delivery,
one day after being sent via a reputable nationwide overnight courier service or two days after deposit in the mail or on the next
business day following transmittal via facsimile. Notices under this Agreement shall be sent to the following representatives of
the Parties:

 

	If to the Company:
	 	 
	Name:	Kenneth S. Kornman, DDS, PhD
	Title:	President and CEO 
	Address:	135 Beaver Street
	 	Waltham, MA 02452
	Phone: 	(781) 398-0700
	E-mail:	kkornman@ilgenetics.com
	 	 
	If to Danforth:
	 	 
	Name:	Gregg Beloff
	Title:	Managing Director
	Address:	91 Middle Road 
	 	Southborough, MA 01772
	Phone:	1 617 686-7679
	E-mail:	gbeloff@danforthadvisors.com

  

		16.	Assignment and Successors. This Agreement may
not be assigned by a Party without the consent of the other which shall not be unreasonably withheld, except that each Party may
assign this Agreement and the rights, obligations and interests of such Party, in whole or in part, to any purchaser of all or
substantially all of its assets or to any successor corporation resulting from any merger or consolidation of such Party with
or into such corporation.

 

		17.	Force Majeure. Neither Party shall be liable for failure of or delay in performing obligations set forth in this Agreement,
and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond
the reasonable control of either Party. In event of such force majeure, the Party affected thereby shall use reasonable efforts
to cure or overcome the same and resume performance of its obligations hereunder.

 

		18.	Headings. The Section headings are intended for convenience of reference only and are not intended to be a part of or
to affect the meaning or interpretation of this Agreement.

 

		19.	Integration; Severability. This Agreement is the sole agreement with respect to the subject matter hereof and shall
supersede all other agreements and understandings between the Parties with respect to the same. If any provision of this Agreement
is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention
of the Parties that the remainder of the Agreement shall not be affected.

 

    	5

    	 

    

  

		20.	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts, excluding choice of law principles. The Parties agree that any action or proceeding arising out of or related in
any way to this Agreement shall be brought solely in a Federal or State court of competent jurisdiction sitting in the Commonwealth
of Massachusetts.

 

		21.	Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which
together will constitute one agreement.

 

If you are in agreement with the foregoing,
please sign where indicated below, whereupon this Agreement shall become effective as of the Effective Date.

  

	DANFORTH ADVISORS, LLC	 	INTERLEUKIN GENETICS, INC.
	 	 	 	 	 
	By:	/s/ Gregg Beloff	 	By:	/s/ Kenneth S. Kornman  
	 	 	 	 	 
	Print Name: 	Gregg Beloff	 	Print Name: 	Kenneth
    S. Kornman, DDS, PhD 
	 	 	 	 	 
	Title:	Managing Director	 	Title:	President and CEO
	 	 	 	 	 
	Date:	  9/8/14	 	Date:	 9/8/14

  

    	6

    	 

    

  

EXHIBIT A

 

Description of Services and Schedule
of Fees

 

Danforth will perform mutually agreed to finance, accounting
and other administrative functions (the “Services”) which are necessary to support the achievement of the Company’s
strategic and financial objectives, and the management of the Company’s business.

 

Services:

 

Danforth will provide the Company the following support:

 

CFO Services:

 

		•	Participate in financing activities

 

		•	Ensure compliance with SEC filing and other regulatory requirements

 

		•	Support investor relations activities

 

		•	Oversee the finance and accounting functions

 

		•	Board, Audit, Compensation, and Corporate Governance committee meeting preparation, support and attendance

 

		•	Other CFO services, as needed/requested:

 

		-	Strategic business planning

 

		-	Supplier contract negotiation and cost reduction planning

 

		-	Corporate and business development/licensing support

 

		-	Financial modeling, planning and analysis

 

		-	Strategic opportunity assessment

 

		-	Stock option plan management

 

		-	Capitalization table management

 

CFO services
will be provided by Steve DiPalma, Managing Director of Danforth.

 

Controller

 

All duties consistent with the role of Controller including,
but not limited to:

 

		•	Support external reporting, including SEC filings

 

		•	Ensure compliance with Sarbanes-Oxley requirements

 

		•	Maintain internal controls

 

		•	Maintain the current accounting system and general ledger

 

		•	Manage monthly close process

 

		•	Reconcile cash accounts, track cash usage, prepare cash flow projections

 

		•	Perform cost analysis

 

		•	Oversee accounting services, such as A/P and payroll, and benefits maintenance

 

		•	Manage the preparation of budgets and forecasts and internal financial reports, with variance analysis

 

		•	Vendor management (including all contracts, suppliers, W-9s and issuing 1099s)

 

		•	Financial policies, procedures and controls review

 

    	7

    	 

    

  

Other Services:

 

Danforth also offers Contract Management Services, which entails
all duties consistent with the role of contracts manager including, but not limited to, supporting the Company with:

 

		•	Review contracts management system and ensure company agreements are organized;

		•	Develop index to company agreements, as approved by Company;

		•	Draft, review and finalize company agreements as necessary;

		•	Assist Company outside counsel with review and negotiation of company contracts;

		•	Additional special projects as may be requested by Company

  

The Parties recognize that the time required to provide the
Services will fluctuate, depending on the Company’s needs and priorities, and to some extent external events that cannot
be controlled or accurately predicted. Therefore, the Parties will meet as soon as possible after the execution of this Agreement
to agree on the prioritization of tasks and the level of resources required, and will meet periodically, but no less frequently
than monthly, to re-assess resourcing.

  

Fee Schedule:

 

	CFO: Steve DiPalma	$275/hour
	Controller:	$165/hour
	Contracts Manager: Ellen Wing:	$130/hour

 

Equity Compensation

 

The Company and Danforth will execute under separate agreement
provisions to provide Danforth warrants under the following terms:

 

		•	The Company will issue to Danforth warrants to purchase 100,000 shares of the Company’s common stock as of the Effective
Date of this Agreement.

 

		•	The warrants will have an exercise price equal to the closing price of the Company’s common stock on the Effective Date
of this Agreement.

 

		•	The warrants shall vest on a monthly basis over two years in equal monthly amounts.

 

		•	The warrants will have a term of 10 years.

 

		•	All warrants shall be fully vested and exercisable upon a Change of Control.

 

		•	50% of the warrants shall be fully vested and exercisable if the Company terminates for any reason other than “for cause”
before the first anniversary of the agreement; the remaining 50% of the warrants shall be fully vested and exercisable if the Company
terminates for any reason other than “for cause” upon the extension of the agreement past the first anniversary of
the agreement.

 

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]